Delaware court dismisses Accord claims in Seroquel antitrust litigation
Shutterstock/LMWH
Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10